Recent Company News

• 02:33 AM ET Mar 30, 2026
  

  Bayer's Kerendia approved in EU for new indication in adult patients with heart failure with LVEF ≥40% (€38.26, 0.00)

• 12:09 PM ET Mar 27, 2026
  

  StreetAccount Activist Summary: Week of 23-Mar

• 04:52 AM ET Mar 20, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 03:52 AM ET Mar 20, 2026
  

  StreetAccount Summary - European pre-market trading update

• 07:55 PM ET Mar 23, 2026
  

  Activist Jeff Ubben seeking to sell stake in Bayer - Bloomberg (€38.47, 0.00)

• 03:32 AM ET Mar 23, 2026
  

  Bayer's Eylea 8 mg approved for third retinal indication in Japan (€38.39, 0.00)

• 02:39 AM ET Mar 23, 2026
  

  Bayer announces first approval for low-dose MRI contrast agent in Japan (€38.39, 0.00)

• 08:50 AM ET Mar 20, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market